Fig. 5

SS-31 administration after sepsis development prevents mitochondrial abnormalities from occurring. A Heatmap of DEGs reveal the patterns of SS-31-treated sepsis survivors shift towards naïve controls from vehicle-treated sepsis survivors. B PCA indicates clear differences between non-sepsis controls (red) and sepsis survivors, while SS-31 treated sepsis survivors (blue) cluster in between the two other groups. C NADH and SDH activity staining in TA muscle sections indicates SS-31 protects against sepsis-induced decreases as shown in the representative images and quantification. Scale bars represent 100 μm. D TEM analyses to assess mitochondrial morphology in EDL muscle sections. Representative images of vehicle- and SS-31- treated sepsis survivors (n = 3 each) are shown. Yellow and red arrow heads indicate examples of mitochondria with ruptured mitochondrial membranes and organelles with disrupted cristae/centralization into a vacuole-like structure, respectively. White squares in 5,000x images indicate the area of 15,000x images. Black scale bars indicate 500 nm. There are clear trends indicating that SS-31 confers protection against sepsis induced mitochondrial damage. **P < 0.01 and ***P < 0.001